Historique
Article de Périodique
Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence (2011)
Auteur(s) :
HALL, W. ;
GARTNER, C.
Année
2011
Page(s) :
191-196
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
Refs biblio. :
52
Domaine :
Drogues illicites / Illicit drugs ; Tabac / Tobacco / e-cigarette
Thésaurus mots-clés
COCAINE
;
TABAC
;
NICOTINE
;
VACCINATION
;
TRAITEMENT
;
PREVENTION
;
RECHUTE
;
ETHIQUE
;
DEPENDANCE
;
ANTICORPS
Résumé :
PURPOSE OF REVIEW: To describe the rationale of vaccines against cocaine and nicotine, to review progress in developing and trialing vaccines to treat dependence on these drugs and to discuss some of the ethical issues that may arise from their use in legally coerced addiction treatment or for prevention of addiction in adolescents.
RECENT FINDINGS: Several randomized controlled trials of cocaine and nicotine vaccines for relapse prevention have produced mixed results. The studies demonstrate that it is possible to raise antibodies to cocaine and nicotine in humans. In abstinent patients who show high levels of drug antibodies, the rewarding effects of these drugs are attenuated. Phase 2 trials have not found nicotine vaccines to be superior to placebo because only a third of those vaccinated develop sufficient levels of antibody to block the effects of nicotine.
SUMMARY: Vaccines are a novel approach to relapse prevention that need to more reliably induce immunity in a larger proportion of vaccinated patients if they are to protect against relapse after achieving abstinence. Vaccines are unlikely to prevent addiction in adolescents. Their use under legal coercion should only be considered after considerable experience with their use in voluntary patients.
RECENT FINDINGS: Several randomized controlled trials of cocaine and nicotine vaccines for relapse prevention have produced mixed results. The studies demonstrate that it is possible to raise antibodies to cocaine and nicotine in humans. In abstinent patients who show high levels of drug antibodies, the rewarding effects of these drugs are attenuated. Phase 2 trials have not found nicotine vaccines to be superior to placebo because only a third of those vaccinated develop sufficient levels of antibody to block the effects of nicotine.
SUMMARY: Vaccines are a novel approach to relapse prevention that need to more reliably induce immunity in a larger proportion of vaccinated patients if they are to protect against relapse after achieving abstinence. Vaccines are unlikely to prevent addiction in adolescents. Their use under legal coercion should only be considered after considerable experience with their use in voluntary patients.
Affiliation :
Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia